基于FibrosisNet网络的心脏纤维化自动诊断使用CMR缺血性心肌病
Mohamed Bekheet1,2, Mohammed Sallah3, Norah S Alghamdi4
1Applied Mathematical Physics Research Group, Physics Department, Faculty of Science, Mansoura University, Mansoura 35516, Egypt.
Diagnostics (Basel, Switzerland)
|February 10, 2024
概括
早期发现心肌纤维化对于改善缺血性心脏病的结果至关重要. 一个新的深度学习模型,FibrosisNet,使用磁共振成像准确地识别和分类心脏纤维化,增强诊断能力.
科学领域:
- 心脏病学 心脏病学
- 医疗成像医学成像
- 人工智能的人工智能
背景情况:
- 缺血性心脏病是导致死亡的主要原因,早期识别可以提高治疗疗效和生存率.
- 心肌纤维化是缺血性心脏病的关键因素,会损害心脏功能,并与不良心血管事件有关.
- 心脏磁共振 (CMR) 成像对于检测纤维化至关重要,纤维化是缺血性心脏病的重要危险因素.
研究的目的:
- 引入一个新的深度学习 (DL) 网络,FibrosisNet,用于准确检测和分类心肌纤维化.
- 评估FibrosisNet在使用磁共振成像 (MRI) 数据诊断心脏纤维化中的性能.
- 将FibrosisNet的疗效与现有的最先进的方法和先进的卷积神经网络 (CNN) 方法进行比较.
主要方法:
- 开发FibrosisNet,这是一个深度网络,包含17个连续层用于纤维化检测.
- 培训和评估FibrosisNet分类系统的最佳性能.
- 在已建立的CNN架构上应用深度转移学习模型来检测纤维化.
主要成果:
- 纤维化网络实现了高性能指标:96.05%的准确度,97.56%的灵敏度,96.54%的F1-Score.
- 该研究表明,与当前最先进的方法相比,FibrosisNet的性能优越.
- 实验结果证实了FibrosisNet在检测和分类心脏纤维化方面的有效性.
结论:
- FibrosisNet代表了心肌纤维化早期和准确诊断的重大进展.
- 拟议的DL模型通过改善治疗结果和缺血性心脏病患者存活率,为患者提供了实质性的医疗益处.
- 在临床实践中,FibrosisNet是一个有价值的工具,可用于治疗心脏纤维化患者.
相关概念视频
Imaging Studies for Cardiovascular System IV: CMRI
541
Cardiovascular magnetic resonance imaging, or CMRI, is a non-invasive diagnostic test that employs a magnetic field and radiofrequency waves to create precise images of the heart and arteries. It provides comprehensive information about cardiac anatomy, function, perfusion, and tissue characterization without ionizing radiation.IndicationsCMRI diagnoses various heart conditions, including tissue damage from heart attacks, ischemic heart disease, myocarditis, aortic issues (tears, aneurysms,...
541
Cardiomyopathy I: Introduction and Classification
826
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
826
Cardiomyopathy II: Dilated Cardiomyopathy
790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy III: Hypertrophic Cardiomyopathy
805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy IV: Restrictive Cardiomyopathy
952
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
952


